Advertisement
Another option for immunotherapy
It nearly doubles median disease-free survival
Will we see this major breakthrough in 2019?
Daratumumab is effective and safe
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Gene expression analysis uncovers clues
Study first to compare rates for mRCC medical oncology
Novel drugs included in therapy
Test helpful for SLN-negative, stage I to IIA and thin tumors
Refractory patients respond to combination therapy
First agent in a new class of noncytotoxic cancer drugs
Advertisement
Advertisement